

David Leppert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/561316/publications.pdf>

Version: 2024-02-01

44
papers

3,275
citations

331670

21
h-index

254184

43
g-index

44
all docs

44
docs citations

44
times ranked

3332
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. <i>Multiple Sclerosis Journal</i> , 2022, 28, 573-582.	3.0	17
2	Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210805.	3.5	8
3	Development of an age-adjusted model for blood neurofilament light chain. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 444-453.	3.7	19
4	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. <i>Lancet Neurology</i> , The, 2022, 21, 246-257.	10.2	210
5	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. <i>Annals of Neurology</i> , 2022, 91, 814-820.	5.3	7
6	Blood Neurofilament Light in Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	18
7	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. <i>Frontiers in Neuroscience</i> , 2022, 16, 819010.	2.8	15
8	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 682.	9.0	41
9	A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 92, 486-502.	5.3	28
10	Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2081-2089.	3.0	2
11	Serum neurofilament light chain as outcome marker for intensive care unit patients. <i>Journal of Neurology</i> , 2021, 268, 1323-1329.	3.6	11
12	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2021, 89, 610-616.	5.3	68
13	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 388-393.	2.0	8
14	Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. <i>Critical Care</i> , 2021, 25, 32.	5.8	16
15	Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. <i>Journal of Neurology</i> , 2021, 268, 2570-2577.	3.6	14
16	Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study. <i>BMC Medicine</i> , 2021, 19, 38.	5.5	24
17	Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. <i>Brain Communications</i> , 2021, 3, fcab084.	3.3	14
18	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. <i>Journal of Neuroinflammation</i> , 2021, 18, 105.	7.2	44

#	ARTICLE	IF	CITATIONS
19	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 477-489.	5.3	16
20	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	3.0	9
21	Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. <i>Brain Communications</i> , 2021, 3, fcab240.	3.3	9
22	Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands. <i>Frontiers in Immunology</i> , 2021, 12, 811351.	4.8	4
23	Factors influencing serum neurofilament light chain levels in normal aging. <i>Aging</i> , 2021, 13, 25729-25738.	3.1	38
24	Serum NfL levels should be used to monitor multiple sclerosis evolution – Yes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 17-19.	3.0	7
25	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 97-102.	3.0	31
26	Serum neurofilament light chains in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e895.	6.0	1
27	Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis. <i>Journal of Neuroinflammation</i> , 2020, 17, 293.	7.2	22
28	Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2213-2220.	3.7	27
29	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	27
30	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	43
31	Neurofilaments: neurobiological foundations for biomarker applications. <i>Brain</i> , 2020, 143, 1975-1998.	7.6	167
32	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. <i>Neurology</i> , 2020, 94, e2457-e2467.	1.1	61
33	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 945-955.	3.7	35
34	Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. <i>Journal of Neurology</i> , 2020, 267, 3476-3478.	3.6	83
35	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	24
36	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. <i>Nature Communications</i> , 2020, 11, 812.	12.8	316

#	ARTICLE	IF	CITATIONS
37	Serum neurofilament light chain and optical coherence tomography measures in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	22
38	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. <i>JAMA Neurology</i> , 2019, 76, 1359.	9.0	129
39	Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. <i>Neurology</i> , 2019, 93, e1299-e1311.	1.1	129
40	Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. <i>Neurology</i> , 2019, 92, e1007-e1015.	1.1	346
41	Blood neurofilament light chain at the doorstep of clinical application. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e599.	6.0	24
42	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 2382-2391.	7.6	345
43	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2017, 81, 857-870.	5.3	768
44	Fluid biomarker and electrophysiological outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1600-1613.	3.0	28